Study on potential differentially expressed genes in idiopathic pulmonary fibrosis by bioinformatics and next generation sequencing data analysis
Basavaraj Mallikarjunayya VastradiD, Chanabasayya Mallikarjunayya VastradiD
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with reduced quality of life and earlier mortality, but its pathogenesis and key genes are still unclear. In this investigation, bioinformatics was used to deeply analyze the pathogenesis of IPF and related key genes, so as to investigate the potential molecular pathogenesis of IPF and provide guidance for clinical treatment. Next generation sequencing dataset GSE213001 was obtained from Gene Expression Omnibus (GEO), the differentially expressed genes (DEGs) were identified between IPF and normal control group. The DEGs between IPF and normal control group were screened with the DESeq2 package of R language. The Gene Ontology (GO) and REACTOME pathway enrichment analyses of the DEGs were performed.. Using the g:Profiler, the function and pathway enrichment analysis of DEGs were performed. Then, a protein-protein interaction (PPI) network was constructed via the Integrated Interactions Database (IID) database. Cytoscape with Network Analyzer was used to identify the hub genes. miRNet and NetworkAnalyst database was used to construct the targeted microRNAs (miRNAs) and transcription factors (TFs) of the hub genes. Finally receiver operating characteristic (ROC) curve analysis was used to validates the hub genes. A total of 958 DEGs were screened out in this study, including 479 up regulated genes and 479 down regulated genes. Most of the DEGs were significantly enriched in response to stimulus, GPCR ligand binding, microtubule-based process and defective GALNT3 causes HFTC. In combination with the results of the PPI network, miRNA-hub gene regulatory network and TF-hub gene regulatory network, hub genes including LRRK2, BMI1, EBP, MNDA, KBTBD7, KRT15, OTX1, TEKT4, SPAG8 and EFHC2 were selected. Our findings will contribute to identification of potential biomarkers and novel strategies for the treatment of IPF, and provide a novel strategy for clinical therapy.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A novel proliferative candidate genes panel for idiopathic pulmonary fibrosis: insights from integrated bulk and single-cell RNA sequencing
Q. Daniel Wang, Chunli Tang, … Yubao Wang·bioRxiv·Feb 22, 2026
- Unraveling the Pathogenesis of Idiopathic Pulmonary Fibrosis Complicated with Type 2 Diabetes through Microarray Data Analysis
Zihan Xu·bioRxiv·Jul 31, 2023
- Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasets
Daniel Chin, Tamara Hernández-Beeftink, … Louise V. Wain·European Respiratory JournalPeer-reviewed·May 21, 2026
- Pan-transcriptome-based Candidate Therapeutic Discovery for Idiopathic Pulmonary Fibrosis
Yunguan Wang, Jaswanth Yella, … Anil Goud Jegga·Therapeutic Advances in Respiratory DiseasePeer-reviewed·Jan 1, 2020
- Single cell transcriptomics in a treatment-segregated cohort exposes a STAT3-regulated therapeutic gap in idiopathic pulmonary fibrosis
Neil J. McKenna, Scott A. Ochsner, … Iván O. Rosas·bioRxiv·Jun 16, 2025
- Integrated RNA sequencing reanalysis reveals reproducible matrix-immune signatures in idiopathic pulmonary fibrosis
Sneha Nandimandalam, Jin He, George I. Mias·bioRxiv·Jun 29, 2026